摘要Diabetes mellitus results in numerous complications.Diabetic pulmonary fibrosis(DPF),a late pulmonary complication of diabetes,has not attracted as much attention as diabetic nephropathy and cardiomyopathy.Mangiferin(MF)is a natural small molecular compound that exhibits a variety of pharmacological effects including anti-inflammatory,anti-cancer,anti-diabetes,and anti-fibrosis effects.In this study,we investigated whether long-term diabetes shock induces DPF,and explored whether MF had a protective effect against DPF.We first examined the lung tissues and sections of 20 diabetic patients obtained from discarded lung surgical resection specimens and found that pulmonary fibrosis mainly accumulated around the pulmonary vessels,accompanied by significantly enhanced endothelial-mesenchymal transition(EndMT).We established a mouse model of DPF by STZ injections.Ten days after the final STZ injection,the mice were administered MF(20,60 mg/kg,i.g.)every 3 days for 4 weeks,and kept feeding until 16 weeks and euthanized.We showed that pulmonary fibrotic lesions were developed in the diabetic mice,which began around the pulmonary vessels,while MF administration did not affect long-term blood glucose levels,but dose-dependently alleviated diabetes-induced pulmonary fibrosis.In human umbilical vein endothelial cells(HUVECs),exposure to high glucose(33.3 mM)induced EndMT,which was dose-dependently inhibited by treatment with MF(10,50 μM).Furthermore,MF treatment promoted SIRT3 expression in high glucose-exposed HUVECs by directly binding to AMPK to enhance the activity of FoxO3,which finally reversed diabetes-induced EndMT.We conclude that MF attenuates DPF by inhibiting EndMT through the AMPK/FoxO3/SIRT3 axis.MF could be a potential candidate for the early prevention and treatment of DPF.